eldelumab   Click here for help

GtoPdb Ligand ID: 9047

Synonyms: BMS-936557 | MDX-1100
Immunopharmacology Ligand
Compound class: Antibody
Comment: Eldelumab (BMS-936557 and formerly MDX-1100) is a a fully human monoclonal antibody targeting the chemokine CXCL10 (a.k.a. interferon-γ-inducible protein-10 or IP-10) [1]. It is being investigated for its anti-inflammatory action in autoimmune conditions.
BLAST peptide sequence analysis reveals exact matches with heavy and light chain variable regions claimed in patent US8258266, and identify eldelumab as clone 6A5 [1].
No information available.
Summary of Clinical Use Click here for help
Eldelumab has been evaluated in Phase 2 clinical trials for rheumatoid arthritis [3] and ulcerative colitis (NCT00656890) [2]. The antibody showed efficacy in both conditions.
Mechanism Of Action and Pharmacodynamic Effects Click here for help
Eldelumab potently binds CXCL10 and prevents it from binding to its receptor CXCR3. CXCR3 is expressed only on activated T cells. Antibody-induced blockade of CXCR3 activation is expected to produce an anti-inflammatory effect.